

Shan-liang Zhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1533024/publications.pdf>

Version: 2024-02-01

33
papers

2,023
citations

236925

25
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

3019
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs. <i>PLoS ONE</i> , 2014, 9, e95240.	2.5	323
2	Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. <i>Tumor Biology</i> , 2014, 35, 10773-10779.	1.8	201
3	miR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. <i>Gene</i> , 2013, 531, 8-14.	2.2	132
4	Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. <i>Tumor Biology</i> , 2014, 35, 9649-9659.	1.8	126
5	Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer. <i>Gene</i> , 2017, 623, 5-14.	2.2	102
6	Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222. <i>Tumor Biology</i> , 2016, 37, 3227-3235.	1.8	89
7	Î²-Elemente Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes. <i>Cellular Physiology and Biochemistry</i> , 2015, 36, 2274-2286.	1.6	83
8	MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. <i>Gene</i> , 2017, 596, 110-118.	2.2	81
9	Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. <i>Tumor Biology</i> , 2016, 37, 5247-5256.	1.8	79
10	MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes. <i>Oncotarget</i> , 2016, 7, 19601-19609.	1.8	74
11	MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3Î² signaling pathway. <i>Gene</i> , 2016, 593, 84-90.	2.2	72
12	The role of miRNAs in drug resistance and prognosis of breast cancer formalin-fixed paraffin-embedded tissues. <i>Gene</i> , 2016, 595, 221-226.	2.2	63
13	miR-29a: a potential therapeutic target and promising biomarker in tumors. <i>Bioscience Reports</i> , 2018, 38, .	2.4	62
14	Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 122-131.	3.9	51
15	Microenvironment-induced TIMP2 loss by cancer-secreted exosomal miR-4443 promotes liver metastasis of breast cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 5722-5735.	4.1	48
16	Circular RNA hsa_circ_0000993 inhibits metastasis of gastric cancer cells. <i>Epigenomics</i> , 2018, 10, 1301-1313.	2.1	43
17	miR-4443 Participates in the Malignancy of Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0160780.	2.5	34
18	Circular RNA circASS1 is downregulated in breast cancer cells MDA-MB-231 and suppressed invasion and migration. <i>Epigenomics</i> , 2019, 11, 199-213.	2.1	34

#	ARTICLE	IF	CITATIONS
19	miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway. <i>Tumor Biology</i> , 2016, 37, 15315-15324.	1.8	32
20	Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis. <i>European Journal of Clinical Nutrition</i> , 2018, 72, 4-17.	2.9	31
21	MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3 β / β -Catenin Signaling Pathway. <i>PLoS ONE</i> , 2016, 11, e0153194.	2.5	29
22	Pre-mir-27a rs895819 polymorphism and cancer risk: a meta-analysis. <i>Molecular Biology Reports</i> , 2013, 40, 3181-3186.	2.3	28
23	Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression. <i>Gene</i> , 2017, 622, 1-12.	2.2	28
24	MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells. <i>Tumor Biology</i> , 2014, 35, 6327-6334.	1.8	27
25	Prevalence of human papillomavirus infection of 65,613 women in East China. <i>BMC Public Health</i> , 2019, 19, 178.	2.9	27
26	Nonoccupational physical activity and risk of ovarian cancer: a meta-analysis. <i>Tumor Biology</i> , 2014, 35, 11065-11073.	1.8	26
27	Methionine synthase A2756G polymorphism and breast cancer risk: An up-to-date meta-analysis. <i>Gene</i> , 2013, 527, 510-515.	2.2	24
28	Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis. <i>Disease Markers</i> , 2015, 2015, 1-8.	1.3	21
29	miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27kip1 expression. <i>Gene</i> , 2016, 590, 44-50.	2.2	19
30	MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells. <i>Gene</i> , 2015, 556, 113-118.	2.2	17
31	The m ⁶ A-related gene signature for predicting the prognosis of breast cancer. <i>PeerJ</i> , 2021, 9, e11561.	2.0	8
32	CircATRNL1 and circZNF608 Inhibit Ovarian Cancer by Sequestering miR-152-5p and Encoding Protein. <i>Frontiers in Genetics</i> , 2022, 13, 784089.	2.3	6
33	Identification and validation of tumor microenvironment-related prognostic biomarkers in breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 0-0.	1.0	3